rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ASMB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Assembly Bio at UBS biopharma conference: pipeline widens, catalysts loom
      Nov 16Investing.comASMBUBS
      Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates

      Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -111.36% and -63.95%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 12Yahoo FinanceASMB
      Assembly Biosciences: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceASMB
      Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
      Nov 12Yahoo FinanceASMB
      Assembly Biosciences at guggenheim: pipeline gains, cash runway and key tests
      Nov 10Investing.comASMB
      Assembly Biosciences to Participate in Upcoming Investor Conferences
      Nov 2Yahoo FinanceASMB
      Assembly Biosciences starts phase 2 trial of HDV treatment
      Oct 29Investing.comASMB
      Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
      Oct 29Yahoo FinanceASMB
      Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Assembly Biosciences (ASMB)

      Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailACADASMB
      Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program
      Oct 5Yahoo FinanceASMB
      Assembly Biosciences to present ABI-6250 phase 1a data at AASLD
      Oct 5Investing.comASMB
      Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
      Oct 5Yahoo FinanceASMB
      New Strong Buy Stocks for September 17th

      Detailed price information for Movado Group Inc (MOV-N) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailASMBMTG
      Assembly Biosciences at H.C. Wainwright conference: pipeline gains traction
      Sep 16Investing.comASMB
      Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

      SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. A live webcast will be available on the Events and Presentations section of Assembly Bio’s website, and a replay will be

      Sep 10Yahoo FinanceASMB
      Why is Assembly Biosciences stock surging today?
      Sep 8Investing.comASMB
      Assembly Bio stock gains after exercising Gilead profit option
      Sep 8Investing.comASMB
      Assembly Bio opts into 40% U.S. profit share for herpes drug
      Sep 8Investing.comASMB
      Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services

      EuroDry, RCM Technologies, Assembly Biosciences, Delcath Systems and National Energy Services show strong price momentum after August's market gains.

      Sep 8Yahoo FinanceASMBDCTHEDRYNESR
      Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
      Sep 8Yahoo FinanceASMB
      Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High?

      The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Sep 7Yahoo FinanceASMB
      Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going
      Sep 3Yahoo FinanceASMB
      Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Assembly Biosciences (ASMB)

      Detailed price information for Tempus AI Cl A (TEM-Q) from The Globe and Mail including charting and trades.

      Sep 2The Globe and MailASMBTEM
      UBS initiates Assembly Biosciences stock with buy rating on antiviral platform
      Sep 1Investing.comASMB
      Mizuho lowers Assembly Biosciences stock price target to $45
      Aug 31Investing.comASMB
      Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

      The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

      Aug 26Yahoo FinanceASMBDRUG

      This is the newest page. Registered accounts read further back.